Yahoo
Paris - Delayed Quote EUR

ABIVAX Société Anonyme (ABVX.PA)

77.15 -0.50 (-0.64%)
At close: November 6 at 5:36:06 PM GMT+1
Chart Range Bar
Loading chart for ABVX.PA
  • Previous Close 77.65
  • Open 74.45
  • Bid --
  • Ask --
  • Day's Range 73.80 - 77.15
  • 52 Week Range 60.45 - 139.00
  • Volume 161,373
  • Avg. Volume 127,630
  • Market Cap (intraday) 6.754B
  • Beta (5Y Monthly) -0.33
  • PE Ratio (TTM) --
  • EPS (TTM) -5.21
  • Earnings Date Sep 21, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 131.72
  • Moby Rating Neutral

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

www.abivax.com

98

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ABVX.PA
35.92%
CAC 40 (^FCHI)
0.13%

1-Year Return

ABVX.PA
11.93%
CAC 40 (^FCHI)
2.19%

3-Year Return

ABVX.PA
725.13%
CAC 40 (^FCHI)
16.04%

5-Year Return

ABVX.PA
178.52%
CAC 40 (^FCHI)
15.60%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.2M
Earnings -117.43M
Profit Margin -9,777.94%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-150M
-100M
-50M
0
-15000.0%
-10000.0%
-5000.0%

Analyst Insights

View More

Analyst Price Targets

70.00
131.72 Average
77.15 Current
180.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -62.88%

  • Return on Equity (ttm)

    -252.35%

  • Revenue (ttm)

    4.67M

  • Net Income Avi to Common (ttm)

    -401.22M

  • Diluted EPS (ttm)

    -5.21

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    402.38M

  • Total Debt/Equity (mrq)

    0.33%

  • Levered Free Cash Flow (ttm)

    -125.9M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: